




RECEIVED

FEB 26 2003

TECH CENTER 1600/2900

**FIG. 1****FIG. 2**



TECH CENTER 1600/2900

FEB 26 2003

RECEIVED




FIG. 3




FIG. 4



FEB 26 2003

RECEIVED




FIG. 5




FIG. 6




FIG. 7



FIG. 8A




FIG. 8B





FIG. 8C







FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D



RECEIVED
FEB 26 2003
TECH CENTER 1600/2900




FIG. 10

RECEIVED

FEB 26 2003

TECH CENTER 1600/2900




FIG. 11

RECEIVED

FEB 26 2003

TECH CENTER 1600/2900



Title: ANTI-TUMOR ANTIBODY COMPOSITIONS AND
METHODS OF USE
Inventors: Devaux et al.
Genentech Docket No. P177R1

HEAVY CHAIN SEQUENCES OF ANTI-PSCA Mabs

CDR1

CDR2

2395 : N-----ELVKPGAPVKLSCKASGYTFTNYWMNVKQRPGRGLEWIGRIDPSXXXQTFKDKA
2399 : N-----PGAELVKPGAPVKLSCKASGYTFTNYWMNVKQRPGRGLEWIGRIDPSDSETQYNQTFKDKA
2403 : N-QVQVQQPGAELVKPGAPVKLSCKASGYTFTNYWLNWVKQRPGRGLEWIGRIDPSDSEIHYDQKFKDKA
2761 : N-EVQLQQSGPDLEKPGASVKISCKPSGNSFTGYIHWVKQSHGKSLEWIGRVDPNNGFTSYNQKFKDKA

CDR3

2395 : TLTVDKSSSTAYIQLSSLTSEDSAVYYCAITAAIAMDYWGQGTSTVSSAKTTGPS-C
2399 : TLTVDKSSSTAYIQLSSLTSEDSAVYYCAITAAIAMDYWGQGTSTVSSAKTTGPS-C
2403 : TLTVDKSSSTAYIQLSSLTSEDSAVYYCALTGIYAMAYWGQGTSTVSSAKTTGPS-C
2761 : ILTVDKSSSTAYMELSLTSEDSAVYYCVG-NFFDS--WGQGTTLTVSSAKTTGPS-C

LIGHT CHAIN SEQUENCES OF ANTI-PSCA Mabs

CDR1

CDR2

2395 : N-----SVSISCRSSKSLLLHSNGNTYLYWFLQRPQSPQLLIYRMSNLAGVPPDRFS
2403 : N-DIVMTQAAPSPVPTPGESVSISCRSSKSLLLHSNGNTYLYWFLQRPQSPQLLIYRMSNLAGVPPDRFS
2761 : N-DVVMQTPTPLTSLVTIGQPASISCKSSQSLDSDGKTYLNWLLQRPQSPKRLIYLVSTLDSGVPPDRFT

CDR3

2395 : GSGSGTVFTLRISRVEAEDGVYYCMQHLESPTFFGSGTKLEIKR-C
2403 : GSGSGTAFTLRISRVEAEDGVYYCLOHLEYPTFFGGGTKLEIKR-C
2761 : GSGSGTDFTLKRISRVEAEDLGVIYCWQGTFFRFFGGGTKLEIKR-C

FIG. 12

RECEIVED

FEB 26 2003

TECH CENTER 1600/2900

FIG. 13

chimeric 2403 (5F2.4H4.1E3) Light Chain

signal peptide MGWSCIILFLVATATGVHS

DIVMTQAAPSPVTPGESVSISCRSSKSLLSHNGNTYLYWFLQRPQSPQLLIYRMSNLASGVDPDRFSGSGGTAFTLRISRVEAEDVG
VYVCLQHLEYPYTFGGGKLELK/RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

chimeric 2403 (5F2.4H4.1E3) IgG Heavy Chain

signal peptide MGWSCIILFLVATATGVHS

QVQVQQPGAELVKPGAPVKLSCKASGYTFTNYWLNWVKQRPGRGLEWIGRIDPSDEIHVDQKFKDKATLTVDKSSSTAYIQLSSLT
SEDSAVYYCALTGIYAMAYWGQTSVTVSSAKTTG/PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSVVTVPSSSLGTQTYICNVNHHKPSNTKVDKKVEPKSCDKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
DVSHEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
LPDSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVCSVMHEALHNHYT
QKSLSLSPGK

chimeric 2761 (6B8.1D7.2B3) Fab - Light Chain

DVVMTQTPLTSLVTIGQPASISCKSSQSLDSDGKTYLNLWLLQRPQSPKRLIYLVSTLDSGVDPDRFTGSGSGTDFTLKISRVEAEDLGV
YYCWQGTHFPRTFGGGTKLEIKR [V_L/C_k junction]
TVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLSKADYEKHKVYACET
HQGLSSPVTKSFNRGEC

chimeric 2761 (6B8.1D7.2B3) Fab - Heavy chain

EVQLQQSGPDLEKPGASVKISCKPSGNSFTGYIHWVKQSHGKSLEWIGRVDPNNGFTSYNQKFKGKAILTVDKSSSTAYMELRSLTSE
DSAVYYCVGNFFDSWGQGTTLTVSSA [V_H/C_γ1 junction]
KTTGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHHKPSN
TKVDKKVEPKSCDKTHT



Title: ANTI-TUMOR ANTIBODY COMPOSITIONS AND
METHODS OF USE
Inventors: Devaux et al.
Genentech Docket No. P1777R1



RECEIVED
FEB 26 2003
TECH CENTER 1600/2900





FIG. 14



TECH CENTER 1600/2900

FEB 26 2003

RECEIVED

1 ATGAAGGCTG TGCTGCTTGC CCTGTTGATG GCAGGCTTGG CCCTGCAGCC AGGCACTGCC
TACTTCCGAC ACGACGAACG GGACAACTAC CGTCCGAACC GGGACGTCGG TCCGTGACGG
1 M K A V L L A L L M A G L A L Q P G T A

61 CTGCTGTGCT ACTCCTGCAA GGCCCAGGTG AGCAACGAGG ACTGCCTGAA TGTGGAGAAC
GACGACACGA TGAGGACGTT CCGGGTCCAC TCGTTGCTCC TGACGGACTT ACACCTCTTG
21 L L C Y S C K A Q V S N E D C L N V E N

121 TGCACGCAGC CGGAGGAGCA GTGCTGGACC GAGCGCATCC GCGCCGTGGG CCTCCTGACC
ACGTGCGTCG GCCTCCTCGT CACGACCTGG CTCGCGTAGG CGCGGCACCC GGAGGACTGG
41 C T Q P E E Q C W T E R I R A V G L L T

181 GTCATCAGCA AAGGCTGCAG CTCAAACCTGC GTGGATGACT CACAGGACTA CTACGTGGGC
CAGTAGTCGT TTCCGACGTC GAGTTTGTGAC CACCTACTGA GTGTCCTGAT GATGCACCCG
61 V I S K G C S S N C V D D S Q D Y Y V G

241 AAGAAGAACA TCACCTGCTG TGACACCGAC TTGTGCAACG CCAGCGGGGC CCATGCACTG
TTCTTCTTGT AGTGGACGAC ACTGTGGCTG AACACGTTGC GGTCGCCCCG GGTACGTGAC
81 K K N I T C C D T D L C N A S G A H A L

301 CAGCCGGCTG CTGCCATCCT GGCACCTGCTC CCTGCACTCA GTCTGCTGCT TTGGAGCCCC
GTCGGCCGAC GACGGTAGGA CCGTGACGAG GGACGTGAGT CAGACGACGA AACCTCGGGG
101 Q P A A A I L A L L P A L S L L L W S P

361 AGACAGCTGT AG
TCTGTGACA TC

121 R Q L O

FIG. 15

RECEIVED

FEB 26 2003

TECH CENTER 1600/2900



```

1  ATGAAGGCTG TGCTGCTTGC CCTGTTGATG GCAGGCTTGG CCCTGCAGCC AGGCACTGCC
   TACTTCCGAC ACGACGAACG GGACAAC TAC CGTCCGAACC GGGACGTCGG TCCGTGACGG
1  M K A V L L A L L M A G L A L Q P G T A

61 CTGTTGTGCT ACTCCTGCAA GGCCCAGGTG AGCAACGAGG ACTGCCTGAA TGTGGAGAAC
   GACAACACGA TGAGGACGTT CCGGGTCCAC TCGTTGCTCC TGACGGACTT ACACCTCTTG
21 L L C Y S C K A Q V S N E D C L N V E N

121 TGCACGCAGC CGGAGGAGCA GTGCTGGACC GAGCGCATCC GCGCCGTGGG CTCCTGACC
   ACGTGCCTCG GCCTCCTCGT CACGACCTGG CTCGCGTAGG CGCGGCACCC GGAGGACTGG
41 C T Q P E E Q C W T E R I R A V G L L T

181 GTCATCAGCA AAGGCTGCAG CTCAAAC TGC GTGGATGACT CACAGGACTA CTACGTGGGC
   CAGTAGTCGT TTCCGACGTC GAGTTTGACG CACCTACTGA GTGTCCTGAT GATGCACCCG
61 V I S K G C S S N C V D D S Q D Y Y V G

241 AAGAAGAACA TCACCTGCTG TGACACCGAC TTGTGCAACG CCAGCGGGGC CCATGCCCTG
   TTCTTCTTGT AGTGGACGAC ACTGTGGCTG AACACGTTGC GGTGCCCCCG GGTACGGGAC
81 K K N I T C C D T D L C N A S G A H A L

301 CAGCCAGCTG CTGCCATCCT GGCAC TGC TCCTGCACTCA GCCTGCTGCT TTGGGGCCCC
   GTCGGTCGAC GACGGTAGGA CCGTGACGAG GGACGTGAGT CGGACGACGA AACCCCGGGG
101 Q P A A A I L A L L P A L S L L L W G P

361 AGACAGCTGT AG
   TCTGTCGACA TC
121 R Q L O

```

FIG. 16

```


          10      20      30      40      50
HUMAN    MKAVLLALLMAGLALQPGTALLCYSCKAQVSNEDCLQVENCTQLGEQCWT
          *****
CYNOMOLGUS MKAVLLALLMAGLALQPGTALLCYSCKAQVSNEDCLNVENCTQPEEQCWT
          10      20      30      40      50

          60      70      80      90     100
HUMAN    ARIRAVGLLTVISKGCSLNCVDDSDQYYVGKKNITCCDTDLNASGAHAL
          *****
CYNOMOLGUS ERIRAVGLLTVISKGCSLNCVDDSDQYYVGKKNITCCDTDLNASGAHAL
          60      70      80      90     100

          110     120
HUMAN    QPAAAILALLPALGLLLWGPQL
          *****
CYNOMOLGUS QPAAAILALLPALSLLLWSPRQL
          110     120

```

FIG. 17



RECEIVED

FEB 26 2003

TECH CENTER 1600/2900




FIG. 18




FIG. 19

FEB 26 2003

TECH CENTER 1600/2900





FIG. 20




FIG. 21

FEB 26 2003

TECH CENTER 1600/2900




FIG. 22




FIG. 23



RECEIVED

FEB 26 2003

TECH CENTER 1600/2900




FIG. 24





FIG. 25



RECEIVED

FEB 26 2003

TECH CENTER 1600/2900




FIG. 26





FIG. 27



RECEIVED

FEB 26 2003

TECH CENTER 1600/2900

- 1) 2399 NAKED, 10mg/kg IP, 2X WEEK, n=7/7
- 2) 6B8 NAKED, 10mg/kg IP, 2X WEEK, n=7/7
- △ 3) ANTI-RAGWEED, 10mg/kg IP, 2X WEEK, n=7/7
- ◇ 4) 2399-DM1, 75 ug/kg IV, 2X WEEK, n=3/7
- ▲ 5) 6B8-DM1, 75 ug/kg IV, 2X WEEK, n=3/7
- 6) ANTI-RAGWEED-DM1, 75 ug/kg IV, 2X WEEK, n=6/7




FIG. 28